Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Antibody rightarrow CDKN2A rightarrow Polyclonal CDKN2A  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • HIV-1 TAT Clade-B Recombinant Protein
 • 24-dehydrocholesterol reductase (DHCR24) ELISA Kit
 • Factor V (F5) Antibody
 • ERCC8 Antibody
 • Adenosine A2b receptor (ADORA2B) Antibody
 • AIF1 - IBA1 Antibody
 • sialic acid binding Ig-like lectin 6 (SIGLEC6) ELISA Kit
 • Wilms tumor 1 (WT1) ELISA Kit
 • 2-oxoglutae dehydrogenase, mitochondrial (OGDH) ELISA Kit
 • Canopy homolog 2 (CNPY2) Recombinant Protein
 • ATP synthase subunit alpha, mitochondrial (Atp5a1) Recombinant Protein
 • Influenza A Virus H3N2 Shangdong 9-93 Native Protein
 • CD28 Antibody
 • 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 ELISA Kit
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

anti-CDKN2A antibody :: Rabbit anti-Human CDKN2A Polyclonal Antibody

Scan QR to view Datasheet Catalog #    MBS2529436
Unit / Price
0.02 mL  /  $110 +1 FREE 8GB USB
0.06 mL  /  $150 +1 FREE 8GB USB
0.12 mL  /  $225 +1 FREE 8GB USB
0.2 mL  /  $360 +1 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

CDKN2A, Polyclonal Antibody

★Popular Item★
 Also Known As   

CDKN2A Polyclonal Antibody

 Product Synonym Names    ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
 Product Gene Name   

anti-CDKN2A antibody

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 OMIM    151623
Section Bar
 Clonality    Polyclonal
 Isotype    IgG
 Host    Rabbit
 Species Reactivity    Human
Section Bar
 Purity/Purification    Affinity purification
 Concentration    1mg/mL (lot specific)
Section Bar
 Immunogen    Synthetic peptide of human CDKN2A
 Buffer    PBS with 0.05% sodium azide, 50% glycerol, pH7.3
Section Bar
 Preparation and Storage    Store at -20 degree C (regular) and -80 degree C (long term). Avoid freeze / thaw cycles.
 Other Notes    Small volumes of anti-CDKN2A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 

Product Description specifically for anti-CDKN2A antibody

   This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53.
 Product Categories/Family for anti-CDKN2A antibody    Cancer; Cell biology
 Applications Tested/Suitable for anti-CDKN2A antibody   

ELISA (EIA), Immunohistochemistry (IHC)

 Application Notes for anti-CDKN2A antibody    IHC: 1:50-1:200
Section Bar
 Immunohistochemistry (IHC) of anti-CDKN2A antibody    Immunohistochemistry of Human thyroid cancer using CDKN2A Polyclonal Antibody at dilution of 1:60
anti-CDKN2A antibody Immunohistochemistry (IHC) (IHC) image
Section Bar
 Immunohistochemistry of anti-CDKN2A antibody    Immunohistochemistry of Human thyroid cancer using CDKN2A Polyclonal Antibody at dilution of 1:60
anti-CDKN2A antibody Immunohistochemistry (IHC) image
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for CDKN2A. It may not necessarily be applicable to this product.
 NCBI GI #    304376272
 NCBI GeneID    1029
 NCBI Accession #    NP_001182061.1 [Other Products]
 NCBI GenBank Nucleotide #    NM_001195132.1 [Other Products]
Section Bar
 UniProt Secondary Accession #    O95440; Q15191; Q5VVJ5; Q96B52; Q9NP05; A5X2G7; D3DRK1 [Other Products]
 UniProt Related Accession #    P42771; Q8N726 [Other Products]
 Molecular Weight    8,731 Da
Table BarTOPTable Bar
 NCBI Official Full Name    cyclin-dependent kinase inhibitor 2A isoform p16gamma
 NCBI Official Synonym Full Names    cyclin-dependent kinase inhibitor 2A
 NCBI Official Symbol    CDKN2A [Similar Products]
 NCBI Official Synonym Symbols   
ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
[Similar Products]
 NCBI Protein Information    cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; CDKN2A; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); multiple tumor suppressor 1
 UniProt Protein Name    Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
 UniProt Synonym Protein Names   
Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A
 Protein Family    CDKN2A-interacting protein
 UniProt Gene Name    CDKN2A [Similar Products]
 UniProt Synonym Gene Names    CDKN2; MTS1; CDK4I; MTS-1; p16-INK4; p16INK4A [Similar Products]
 UniProt Entry Name    CD2A1_HUMAN
Section Bar
 NCBI Summary for CDKN2A    This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
Section Bar
 UniProt Comments for CDKN2A    p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Tumor suppressor; Nucleolus; Cell cycle regulation

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; cytosol; nucleus

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor binding; protein kinase binding

Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of immature T cell proliferation in the thymus; caspase activation; protein destabilization; protein stabilization; transcription, DNA-dependent; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of protein kinase activity; negative regulation of phosphorylation; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; positive regulation of DNA damage response, signal transduction by p53 class mediator; negative regulation of cell growth; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome
Table BarTOPTable Bar
 Research Articles on CDKN2A    1. we identified a possible constitutive epigenetic signature in CDKN2A-mutated melanoma patients
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with anti-CDKN2A antibodyPathways associated with anti-CDKN2A antibody
 Reference Product  PubMed Publications
 CDK4 antibody  >1010 publications with CDKN2A and CDK4
 CCND1 antibody  >885 publications with CDKN2A and CCND1
 TP53 antibody  >668 publications with CDKN2A and TP53
 MYC antibody  >454 publications with CDKN2A and MYC
 MDM2 antibody  >374 publications with CDKN2A and MDM2
 CDK6 antibody  >307 publications with CDKN2A and CDK6
 CDK2 antibody  >272 publications with CDKN2A and CDK2
 NPM1 antibody  >4 publications with CDKN2A and NPM1
 UBC antibody  >1 publications with CDKN2A and UBC
 Products by Pathway  Pathway Diagram
 Apoptosis Pathway antibodies  Apoptosis Pathway Diagram
 Apoptosis Modulation And Signaling Pathway antibodies  Apoptosis Modulation And Signaling Pathway Diagram
 Bladder Cancer Pathway antibodies  Bladder Cancer Pathway Diagram
 Bladder Cancer Pathway antibodies  Bladder Cancer Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle, Mitotic Pathway antibodies  Cell Cycle, Mitotic Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cellular Senescence Pathway antibodies  Cellular Senescence Pathway Diagram
Diseases associated with anti-CDKN2A antibodyOrgans/Tissues associated with anti-CDKN2A antibody
 Disease Name  Pubmed Publications
 Adenocarcinoma Antibodies  >1291 publications with CDKN2A and Adenocarcinoma
 Urogenital Neoplasms Antibodies  >1212 publications with CDKN2A and Urogenital Neoplasms
 Cell Transformation, Neoplastic Antibodies  >742 publications with CDKN2A and Cell Transformation, Neoplastic
 Lymphoma Antibodies  >698 publications with CDKN2A and Lymphoma
 Lung Neoplasms Antibodies  >671 publications with CDKN2A and Lung Neoplasms
 Skin Neoplasms Antibodies  >641 publications with CDKN2A and Skin Neoplasms
 Neoplasms, Experimental Antibodies  >632 publications with CDKN2A and Neoplasms, Experimental
 Glioma Antibodies  >496 publications with CDKN2A and Glioma
 Pancreatic Neoplasms Antibodies  >449 publications with CDKN2A and Pancreatic Neoplasms
 Breast Neoplasms Antibodies  >432 publications with CDKN2A and Breast Neoplasms
 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >932 publications with CDKN2A and Blood
 Skin Antibodies  >814 publications with CDKN2A and Skin
 Lung Antibodies  >813 publications with CDKN2A and Lung
 Brain Antibodies  >515 publications with CDKN2A and Brain
 Liver Antibodies  >477 publications with CDKN2A and Liver
 Bone Antibodies  >389 publications with CDKN2A and Bone
 Lymph Node Antibodies  >336 publications with CDKN2A and Lymph Node
 Lymph Antibodies  >334 publications with CDKN2A and Lymph
 Stomach Antibodies  >301 publications with CDKN2A and Stomach
 Cervix Antibodies  >248 publications with CDKN2A and Cervix
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions